Pylori eradication rate between different durations of this quadruple therapy and Deforolimus purchase still remained further research. Key Word(s): 1. Helicobacter, pylori; 2. Drug therapy; 3. Levofloxacin; 4. Bismuth; Presenting Author: XI LIU Additional Authors: HONG CHENG, WEN GAO, XINHONG DONG, FULIAN HU Corresponding Author: HONG CHENG Affiliations: Peking Unversity First Hospital Objective: Increasing resistance to antibiotics is the main cause of failure in the Helicobacter pylori (H. pylori) eradication. The efficacy of the first-line therapy including proton pump inhibitors plus two antibiotics seems to have decreased. So many patients need to receive rescue therapy for the eradication of H. pylori after
first- or second-line therapies. We designed this study to collect patients who have
received furazolidone-based quadruple rescue therapy for two weeks and evaluate the efficacy, compliance and adverse effects of this regimen. Methods: A total of 210 patients with H. pylori positive [13C-urea breath test or rapid urease test positive] failing in previous treatment at least once were enrolled in this study. The average age of the patients was 51.6 years, ranging from 18 to 83 years. They have received a 14-day quadruple therapy with furazolidone, amoxicillin, bismuth citrate in combination MLN0128 price with proton pump inhibitors. To record the side effect profiles at the end of the treatment, H. pylori eradication was assessed with 13C-urea breath test 4 wk after therapy. Results: Two hundred and ten patients including seventy-two males completed this study. H. pylori eradication rate were 90.4% (190/210) according to per-protocol analyses. Mild and moderate adverse effects such as dizziness, nausea, and diarrhea were reported by 30 patients (14.3%). None of the 30 patients needed treatment
for their side effects. Conclusion: Regarding the eradication rate (PP > 90%), low price, and very low adverse effects, a 14-day quadruple therapy with furazolidone, amoxicillin, bismuth citrate and proton pump inhibitors can be an encouraging regimen for H. pylori infection treatment. Key Word(s): 1. H. pylori; 2. furazolidone; 3. efficacy; 4. safety; Presenting Author: YUEMIAO ZHANG Additional Authors: HONG CHENG, XUEZHI very ZHANG, WEN GAO, XINHONG DONG, FULIAN HU Corresponding Author: HONG CHENG, XUEZHI ZHANG Affiliations: Peking University First Hospital Objective: Antibiotic resistance is the main cause of failure of H. pylori infection treatment, especially when the strains resistant to clarithromycin, metronidazole and quinolone. Tetracycline and furazolidone resistance of H. pylori strains are both rare. The 4th Consensus Report of H. pylori infection in China has recommended tetracycline, furazolidone-containing quadruple regimen can be used for H. pylori eradication. However, the safety of this regimen has always been a concern.